Diabetes


What is diabetes?

We’re pursuing leading, distinctive science in diabetes with the goal of developing life-changing medicines that reduce the global burden and complications of this serious disease. 

Type-2 diabetes occurs when the body builds a resistance to insulin, meaning the body is unable to regulate blood glucose levels.

There is a clinical overlap between diabetes, cardiovascular disease (CVD) and renal diseases. People with type-2 diabetes are two to three times more likely to suffer from heart attacks and strokes compared to those without diabetes, and have a greater risk of chronic kidney disease, which affects more than 30 million adults in the United States alone.

We are committed to better understanding the interconnectivity of diabetes, cardiovascular and renal diseases and taking a holistic, patient-centric approach to disease management. 


What we're working on

We are pursuing high-science research and early-action treatment options to support people living with diabetes.


Disease area resources

A disease of epidemic proportions

Diabetes is a growing disease and an enormous global burden that is projected to affect more than 592 million people by 2035.


References:

1. American Diabetes Association. Facts About Type 2. Accessed 17 August 2017. http://www.diabetes.org/diabetes-basics/type-2/facts-about-type-2.html.

2. World Health Organization. Media Centre. Diabetes Fact Sheet. Reviewed November 2016. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/.

3. Centers for Disease Control and Prevention. National Chronic Kidney Disease Fact Sheet, 2017. Available at http://www.cdc.gov/diabetes/pubs/pdf/kidney_factsheet.pdf.

4. ClinicalTrials.gov. “A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (Dapa-CKD).” Available at https://clinicaltrials.gov/ct2/show/NCT03036150.

5. ClinicalTrials.gov. Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (Dapa-HF). Available at https://clinicaltrials.gov/ct2/show/NCT03036124.


Veeva ID: Z4-6509
Date of expiry: August 2018